Universal Cells — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $12M

Overview

Universal Cells is a private biotechnology company, founded in 2012 and acquired by Astellas Pharma Inc., specializing in creating immune-evasive, allogeneic stem cell lines. Its core technology is a recombinant Adeno-Associated Virus (rAAV)-based, nuclease-free gene editing platform used to engineer pluripotent stem cells with specific HLA modifications. The company operates as a platform and product development engine within Astellas, advancing programs from discovery toward clinical trials. Its mission is to enable off-the-shelf, universally compatible cell therapies for a broad range of diseases.

Cell & Gene Therapy

Technology Platform

Proprietary, nuclease-free gene editing platform using recombinant Adeno-Associated Virus (rAAV) to engineer pluripotent stem cells with HLA modifications for immune evasion, creating universal donor cell lines for allogeneic therapy.

Funding History

1

Total raised:$12M

Series A$12MAlexandria Venture InvestmentsMar 15, 2015

Opportunities

The company is positioned to enable the scalable, off-the-shelf allogeneic cell therapy market by solving the key challenge of immune rejection.

Its platform can be applied to multiple high-value therapeutic areas (e.g., ophthalmology, neurology, diabetes), creating a pipeline-in-a-box opportunity for its parent company, Astellas.

Risk Factors

Key risks include the unproven long-term immune evasion and safety of the edited cells in humans, and intense competition from other companies developing universal donor cells, often using CRISPR-based methods.

Success is also dependent on Astellas's effective development and commercialization of the resulting therapies.

Competitive Landscape

Universal Cells competes in the rapidly growing field of allogeneic, iPSC-derived cell therapies. Key competitors include CRISPR Therapeutics (via its ViaCyte acquisition for diabetes), Century Therapeutics, and other biotechs like Sana Biotechnology. Its primary differentiation is its nuclease-free, rAAV-based editing platform, which emphasizes precision and safety over the more common CRISPR-Cas9 approach.

More companies in Cell & Gene Therapy →More companies in United States →